New Medicines

Pancreatic cancer


New molecular entity
Cancer Vaccines Ltd
Cancer Vaccines Ltd

Development and Regulatory status

Phase II Clinical Trials


A therapeutic vaccine designated as allogeneic cell immunotherapy. It is formulated as a cell suspension and is designed to stimulate tumour antigen-specific T-cells to respond and kill cancer cells. Given as 2 doses, 4 weeks apart.
Incidence rates for pancreatic cancer in the UK are highest in people aged 85 to 89. Each year 47% of all new pancreatic cancer cases in the UK are diagnosed in people aged 75 and over. There is no significant difference in incidence between males and females. Since the early 1990s, incidence rates have increased by 17% in the UK. Rates in females have increased by 17%, and rates in males have increased by 14% [1].
Pancreatic cancer

Trial or other data

Feb 22PI/II trial (NCT03096093) is recruiting [2].
Apr 17PI/II trial to determine the optimal dose for the safe immune restoration and immune response of allogeneic cell immunotherapy (ACIT 1) in patients with pancreatic and other late stage cancers starts (ACIT-1-1001; EudraCT2012-005426-30; NCT03096093). The non-randomised, open-label trial is designed to enrol 34 adults in the UK (at Royal Liverpool University Hospital and The Clatterbridge Cancer Centre NHS Foundation Trust). Participants will be given an intradermal injection of ACIT-1 cellular immunotherapy, a total of 2 doses, 4 weeks apart of either 10e5, 10e6, 10e7 or 3x10e7 cells. For patients with pancreatic or haematological cancer treatment will run concurrently with standard chemotherapy; for patients with other late stage cancers, they will not be receiving any other standard treatment. The study is due to complete collection of primary outcome data in Apr 23 [2].